U4133
URB597
≥98% (HPLC), fatty acid amide hydrolase (FAAH) inhibitor, powder
Synonym(s):
Cyclohexylcarbamic acid 3´-carbamoyl-biphenyl-3-yl ester
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C20H22N2O3
CAS Number:
Molecular Weight:
338.40
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
URB597, ≥98% (HPLC), powder
description
Drug Control: Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet.
Quality Level
assay
≥98% (HPLC)
form
powder
drug control
Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet
color
white
solubility
DMSO: soluble ~14 mg/mL
storage temp.
2-8°C
SMILES string
NC(=O)c1cccc(c1)-c2cccc(OC(=O)NC3CCCCC3)c2
InChI
1S/C20H22N2O3/c21-19(23)16-8-4-6-14(12-16)15-7-5-11-18(13-15)25-20(24)22-17-9-2-1-3-10-17/h4-8,11-13,17H,1-3,9-10H2,(H2,21,23)(H,22,24)
InChI key
ROFVXGGUISEHAM-UHFFFAOYSA-N
General description
URB597 binds to active sites of fatty acid amide hydrolases and inhibits their activity. URB597 alters expression of tyrosine hydroxylase and interacts with abnormal-cannabidiol (Abn-CBD) and peroxisome proliferator-activated receptors (PPARs). URB597 elicits antinociception property via cannabinoid receptor by maintaining endocannabinoid anandamide (AEA) levels. URB597 reduces abnormal hyperactivity in neurons and could be for treatment of seizures and improving synaptic plasticity.
Biochem/physiol Actions
Potent, selective fatty acid amide hydrolase (FAAH) inhibitor.
Preparation Note
URB597 is soluble in DMSO at a concentration that is approximately 14 mg/ml.
Storage Class
11 - Combustible Solids
wgk
WGK 3
ppe
Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1-and FAAH-independent mechanisms
Bosier B, et al.
British Journal of Pharmacology, 169(4), 794-807 (2013)
Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes
Alexander JP and Cravatt BF
Chemistry & Biology, 12(11), 1179-1187 (2005)
Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention
Bowers ME and Ressler KJ
Neuropsychopharmacology, 30, 688-688 (2015)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| U4133-25MG | 04061832950013 |
| U4133-5MG | 04061832950020 |